Bluechiip Limited (ASX:BCT), a leader in the development of sample tracking technology for harsh environments, today announced that it has received $1.62M Research and Development Tax Incentive Refund from the Australian Tax Office for the financial year ended 30 June 2020.
Bluechiip Ltd (ASX:BCT) has developed a wireless tracking solution for the healthcare and life science, security, defence and manufacturing industries which represents a generational change from current methods such as labels (hand-written and pre-printed), barcodes (linear and 2D) and microelectronic integrated circuit (IC)-based RFID (Radio Frequency Identification).
The unique tag is based on MEMS technology and contains no electronics. The tag can either be embedded or manufactured into a storage product, such as vials or bags. Easy identification, along with any associated information from the tag such as temperature can be detected by a reader, which can also sense the temperature of the tagged items. The traditional identification technologies have significant limitations. Whereas a barcode requires a visible tag or line-of-sight optical scan, bluechiip(R) technology does not. Unlike labels, barcodes and RFID, the bluechiip(R) technology can sense the temperature of each item a tag is attached to, or embedded in.
The bluechiip(R) technology has initial applications in the healthcare industry particularly those businesses which require cryogenic storage facilities (biobanks and biorepositories). bluechiip(R) offers the only technology that enables accurate and reliable tracking of products including stem cells, cord blood, and other biospecimens. In addition to functioning in extreme temperatures, the bluechiip(R) tracking solution can survive autoclaving, gamma irradiation sterilization, humidification, centrifuging, cryogenic storage and frosting.
The bluechiip(R) technology has other healthcare applications in pathology, clinical trials and forensics. Several other key markets outside of healthcare include cold-chain logistics/supply chain, security/defence, industrial/manufacturing and aerospace/aviation.
Further information is available at http://www.bluechiip.com
The principal activity of Bluechiip Ltd (ASX:BCT) during the half-year was the development and commercialisation of a wireless tracking solution for the healthcare and life science, security, defence and manufacturing industries.
Bluechiip Ltd (ASX:BCT) sales and marketing teams both in Australia and the United States continue to make progressive negotiations with potential OEMs especially in the IVF and Cell Therapy markets despite current COVID-19 travel restrictions.
Bluechiip Ltd (ASX:BCT) has a world first, highly differentiated technology, with protected IP and a $200M growing target market, with very large adjacent markets.
Lodgement of Open Briefing with Managing Director, Andrew McLellan: Bluechiip's (ASX:BCT) results for Q1FY21, pipeline developments and direct to market strategy.
Bluechiip Limited (ASX:BCT) today released its quarterly cash flow report for the quarter ended 30 September 2020.
In this Open Briefing(R), Managing Director, Andrew McLellan discusses Bluechiip's (ASX:BCT) 2020 financial results, the Annual Report and the outlook for 2021.
The Group reported a consolidated loss after providing for income tax for the financial year ended 30 June 2020 of $4,501,085, compared to a consolidated loss of $3,257,996 for the financial year ended 30 June 2019.
Bluechiip Limited (ASX:BCT) today released its quarterly cash flow report for the quarter ended 30 June 2020.
Bluechiip Ltd (ASX:BCT) Managing Director, Andrew McLellan on Labcon's purported termination of chip supply agreement and Bluechiip's market opportunities.